Immunome, Inc.IMNMNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

seekingalpha.com

Immunome: Upcoming NDA, Valuation, And Investment Case

Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after positive phase 3 RINGSIDE data. Varegacestat demonstrated superior efficacy and safety versus nirogacestat, with an 84% risk reduction in progression or death and a 56% objective response rate. Despite a small addressable market (~3,000 patients), conservative peak global sales are estimated at $280 million, supporting a valuation over 235% above IMNM's current market cap.

businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company's 2024 Induc.

fool.com

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

Sold all 3,185,000 shares of Immunome, estimated at $37.30 million based on quarterly average pricing Quarter-end position value decreased by $37.30 million, reflecting both stock price movement and the sale Represents a 4.92% decrease in Opaleye Management's 13F reportable assets under management Post-trade, Opaleye Management holds zero shares and zero dollar value in Immunome The position accounted for 5.3% of fund AUM in the prior quarter, marking a significant shift in portfolio composition

businesswire.com

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. “Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in.

businesswire.com

Immunome to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date/Time: March 3, 2026, at 9:50 a.m. ET Leerink Partners Global Healthcare Conference Presentation Date/Time: March 10, 2026, at 3 p.m. ET Interested parties can ac.

fool.com

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%

Redmile Group added 695,000 shares of Immunome last quarter; the estimated trade size was $12.20 million based on average prices for the quarter. The quarter-end position value increased by $64.01 million, reflecting both share purchases and price changes.

businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 30,000 shares of common stock to one new employee under the Company's 2024 Induce.

businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 93,000 shares of common stock to three new employees under the Company's 2024 Indu.

businesswire.com

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome's website at www.immunome.com. A replay webcast will b.

defenseworld.net

Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall purchased 4,729 shares of the firm's stock in a transaction on Tuesday, December 30th. The shares were purchased at an average cost of $21.15 per share, with a total value of $100,018.35. Following the completion of the transaction, the chief executive officer owned 665,254 shares

defenseworld.net

Isaac Barchas Sells 383,200 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) Director Isaac Barchas sold 383,200 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares in the company, valued

defenseworld.net

Immunome (NASDAQ:IMNM) CEO Clay Siegall Buys 7,278 Shares of Stock

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CEO Clay Siegall acquired 7,278 shares of the company's stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of $20.48 per share, with a total value of $149,053.44. Following the purchase, the chief executive officer owned 860,525 shares of the company's

seekingalpha.com

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Immunome (IMNM) delivered statistically significant phase 3 RINGSIDE results for varegacestat in progressive desmoid tumors, achieving an 84% risk reduction in progression or death compared to placebo. Varegacestat demonstrated a 56% objective response rate, the highest ever in a randomized desmoid tumor trial, and a marked reduction in tumor volume. I maintain a "Strong Buy" rating, supported by the upcoming NDA filing for varegacestat in Q2 2026 and IM-1021's phase 1 lymphoma data expected in 2026.

businesswire.com

Immunome Announces Pricing of Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and other offe.

defenseworld.net

Immunome Target of Unusually Large Options Trading (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) was the recipient of unusually large options trading activity on Monday. Traders acquired 2,906 call options on the stock. This represents an increase of approximately 347% compared to the typical volume of 650 call options. Wall Street Analysts Forecast Growth A number of analysts recently commented on the

fool.com

Why Immunome Stock Surged Today

A phase 3 study of varegacestat met its primary endpoint. The drug candidate could reduce the risk of disease progression or death in people with desmoid tumors by 84%.

businesswire.com

Immunome Announces Proposed Public Offering of Common Stock

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $400 million of shares of its common stock. All of the shares are being offered by Immunome. In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day.

investors.com

Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA

Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug.

reuters.com

Immunome's experimental drug meets main goal in late-stage study

Immunome said on Monday its experimental drug met main goal in a late-stage study for patients with a rare type of tumor.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance